In Brief: Columbia/HCA
Executive Summary
Columbia/HCA: Amends merger agreement with Value Health so that each outstanding share of Value Health common stock will be exchanged for $20.50 in cash. Under the previous agreement, each share was to be exchanged for .58 shares of Columbia stock, which had an April 14 closing value of $18.20 per share. The merger is expected to be completed in the second quarter of 1997. Value Health also said it has received a letter from MedPartners proposing a merger in which each outstanding share of Value Health stock would be exchanged for 1.1 shares of MedPartners stock...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth